Page last updated: 2024-12-11
carboxycinnamic acid bishydroxamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
carboxycinnamic acid bishydroxamide: inhibits histone decacetylase I & 3; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5353484 |
| CHEMBL ID | 4060412 |
| SCHEMBL ID | 675746 |
| MeSH ID | M0288131 |
Synonyms (28)
| Synonym |
|---|
| cbha , |
| HDINHIB_000062 , |
| histone deacetylase inhibitor ii |
| m-carboxycinnamic acid bis-hydroxamide |
| carboxycinnamic acid bishydroxamide |
| m-carboxycinnamic acid bishydroxamide |
| cbha cpd |
| EC-000.2467 |
| n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide |
| A811679 |
| (e)-n-hydroxy-3-(3-(hydroxyamino)-3-oxoprop-1-en-1-yl)benzamide |
| 174664-65-4 |
| benzamide,n-hydroxy-3-[3-(hydroxyamino)-3-oxo-1-propen-1-yl]- |
| AKOS015899716 |
| CCG-208686 |
| SCHEMBL675746 |
| HMS3648E18 |
| mfcd03453553 |
| J-011025 |
| bdbm50252393 |
| histone deacetylase inhibitor ii - cas 174664-65-4 |
| SR-01000946360-1 |
| sr-01000946360 |
| CHEMBL4060412 , |
| HY-W014004 |
| CS-W014720 |
| n-hydroxy-3-[(1e)-2-(hydroxycarbamoyl)eth-1-en-1-yl]benzamide |
| benzamide, n-hydroxy-3-[3-(hydroxyamino)-3-oxo-1-propen-1-yl]- |
Research Excerpts
Overview
M-carboxycinnamic acid bishydroxamide (CBHA) is a recently developed hybrid polar compound. CBHA is structurally related to hexamethylene bisacetamide.
| Excerpt | Reference | Relevance |
|---|---|---|
| "M-carboxycinnamic acid bishydroxamide (CBHA) is a recently developed hybrid polar compound structurally related to hexamethylene bisacetamide." | ( Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Coffey, DC; Glick, RD; La Quaglia, MP; Marks, PA; Richon, VM; Rifkind, RA; Swendeman, SL, 1999) | 0.86 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have discovered the optimum dosage and time for CBHA treatment: incubating SCNT embryos with 2 μmol/L CBHA for 24 h after activation could increase the blastocyst rate from 12." | ( Epigenetic reprogramming, gene expression and in vitro development of porcine SCNT embryos are significantly improved by a histone deacetylase inhibitor--m-carboxycinnamic acid bishydroxamide (CBHA). Guo, R; Hai, T; Li, W; Song, Y; Wang, L; Wang, Y; Zhou, Q, 2014) | 0.6 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | IC50 (µMol) | 0.0700 | 0.0004 | 0.6196 | 10.0000 | AID1452865 |
| Histone deacetylase 1 | Homo sapiens (human) | IC50 (µMol) | 0.0100 | 0.0001 | 0.5543 | 9.9000 | AID1452863 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (62)
Molecular Functions (24)
Ceullar Components (15)
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1452863 | Inhibition of HDAC1 (unknown origin) | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors. |
| AID1452865 | Inhibition of HDAC3 (unknown origin) | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (22)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.70
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.70) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (4.55%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (95.45%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||